Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $93.3 million.

  • Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) rose 3707.0% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 3707.0%. This contributed to the annual value of $70.0 million for FY2023, which is 1965.23% up from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $93.3 million for Q3 2025, which was up 3707.0% from $89.1 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $93.3 million during Q3 2025, and its lowest value of $6.4 million during Q2 2021.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $67.9 million (recorded in 2024), while the average stood at $57.3 million.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) skyrocketed by 80576.48% in 2022 and then tumbled by 424.66% in 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $6.6 million in 2021, then skyrocketed by 788.13% to $58.5 million in 2022, then rose by 19.65% to $70.0 million in 2023, then dropped by 2.71% to $68.1 million in 2024, then surged by 37.07% to $93.3 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $93.3 million in Q3 2025, compared to $89.1 million in Q2 2025 and $85.7 million in Q1 2025.